Patents by Inventor Haralambos HADJIVASSILIOU

Haralambos HADJIVASSILIOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR REDUCTION OF IMMUNOGENICITY
    Publication number: 20240075133
    Abstract: Provided herein are methods and uses involving the combination of an anti-CD20 antibody, e.g., rituximab with a protein therapeutic, for example, an antibody (e.g., an antibody that specifically binds to human CD47).
    Type: Application
    Filed: June 15, 2023
    Publication date: March 7, 2024
    Inventors: Jeffrey C. Johnson, Lawrence Dearth, Haralambos HADJIVASSILIOU, Jeonghoon Sun, Kandasamy Hariharan
  • BISPECIFIC ANTIBODY TREATMENT OF LYMPHOID MALIGNANT NEOPLASM CONDITIONS
    Publication number: 20230365681
    Abstract: Provided is a method for the treatment of a lymphoid malignant neoplasm in a subject in need thereof comprising administering to the subject an effective amount of a bispecific antibody which comprises a Fab portion that binds CD47 and a Fab portion that binds CD20. In some embodiments, the lymphoid malignant neoplasm is Non-Hodgkin's Lymphoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or primary mediastinal B-cell lymphoma. In certain embodiments, the lymphoid malignant neoplasm is NHL.
    Type: Application
    Filed: October 5, 2021
    Publication date: November 16, 2023
    Inventors: Haralambos HADJIVASSILIOU, Dan ZHU, Jeonghoon SUN, Sharmistha ACHARYA, Jeffrey JOHNSON, Kandasamy HARIHARAN, Ho CHO
  • ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47
    Publication number: 20220340675
    Abstract: Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRP? in tumor cells while exhibiting no substantial binding to CD47 in normal cells.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 27, 2022
    Inventors: Haralambos HADJIVASSILIOU, Dan ZHU, Jeonghoon SUN, Sharmistha ACHARYA, Jeffrey JOHNSON, Henry CHAN, Kandasamy HARIHARAN, Ho CHO
  • Antibodies with low immunogenicity and uses thereof
    Patent number: 11427632
    Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 30, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Jeffrey C. Johnson, Lawrence Dearth, Haralambos Hadjivassiliou, Jeonghoon Sun, Kandasamy Hariharan
  • ENGINEERING OF AN ANTIBODY FOR TUMOR-SELECTIVE BINDING OF CD47
    Publication number: 20220162330
    Abstract: Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRP? in tumor cells while exhibiting no substantial binding to CD47 in normal cells.
    Type: Application
    Filed: April 3, 2020
    Publication date: May 26, 2022
    Inventors: Haralambos HADJIVASSILIOU, Dan ZHU, Jeonghoon SUN, Sharmistha ACHARYA, Jeffrey JOHNSON, Kandasamy HARIHARAN, Ho CHO
  • ANTIBODIES WITH LOW IMMUNOGENICITY AND USES THEREOF
    Publication number: 20190241654
    Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.
    Type: Application
    Filed: July 5, 2017
    Publication date: August 8, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Jeffrey C. JOHNSON, Lawrence DEARTH, Haralambos HADJIVASSILIOU, Jeonghoon SUN, Kandasamy HARIHARAN